Search Results - "Chu, Karen W"

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study by Clark, W Lloyd, Boyer, David S, Heier, Jeffrey S, Brown, David M, Haller, Julia A, Vitti, Robert, Kazmi, Husain, Berliner, Alyson J, Erickson, Kristine, Chu, Karen W, Soo, Yuhwen, Cheng, Yenchieh, Campochiaro, Peter A

“…To determine week 52 efficacy and safety outcomes in eyes with macular edema after branch retinal vein occlusion (BRVO) treated with 2 mg intravitreal…”
Get full text

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study by Campochiaro, Peter A, Clark, W Lloyd, Boyer, David S, Heier, Jeffrey S, Brown, David M, Vitti, Robert, Kazmi, Husain, Berliner, Alyson J, Erickson, Kristine, Chu, Karen W, Soo, Yuhwen, Cheng, Yenchieh, Haller, Julia A

“…To compare the efficacy and safety of intravitreal aflibercept injection (IAI) with macular grid laser photocoagulation for the treatment of macular edema…”
Get full text

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial by Lanzetta, Paolo, Korobelnik, Jean-François, Heier, Jeffrey S, Leal, Sergio, Holz, Frank G, Clark, W Lloyd, Eichenbaum, David, Iida, Tomohiro, Xiaodong, Sun, Berliner, Alyson J, Schulze, Andrea, Schmelter, Thomas, Schmidt-Ott, Ursula, Zhang, Xin, Vitti, Robert, Chu, Karen W, Reed, Kimberly, Rao, Rohini, Bhore, Rafia, Cheng, Yenchieh, Sun, Wei, Hirshberg, Boaz, Yancopoulos, George D, Wong, Tien Y

“…Intravitreal aflibercept 8 mg could improve treatment outcomes and provide sustained disease control in patients with neovascular age-related macular…”
Get full text

INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial by Brown, David M., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Heier, Jeffrey S.

“…The purpose of this study was to compare intravitreal nesvacumab (anti-angiopoietin 2) plus aflibercept with intravitreal aflibercept injection (IAI) in…”
Get full text

Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases by Korobelnik, Jean-François, Lanzetta, Paolo, Wykoff, Charles C, Wong, Tien Y, Zhang, Xin, Morgan-Warren, Peter, Fitzpatrick, Scott, Leal, Sergio, Brunck, Lynne, Hasanbasic, Zoran, Chu, Karen W, Reed, Kimberly, Sivaprasad, Sobha

Get full text

Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial by Heier, Jeffrey S, Wykoff, Charles C, Waheed, Nadia K, Kitchens, John W, Patel, Sunil S, Vitti, Robert, Perlee, Lorah, Chu, Karen W, Leal, Sergio, Asmus, Friedrich, Son, Vladimir, Schmelter, Thomas, Brown, David M

“…To compare the efficacy and safety of intravitreal aflibercept + anti-platelet-derived growth factor receptor β (PDGFRβ) combination with intravitreal…”
Get full text

Effects of Repeated Intravitreal Aflibercept Injection on the Corneal Endothelium in Patients With Age-Related Macular Degeneration: Outcomes From the RE-VIEW Study by Lass, Jonathan H, Benetz, Beth Ann, Menegay, Harry J, Tsipis, Constantinos P, Cook, Jane Caty, Boyer, David S, Singer, Michael, Erickson, Kristine, Saroj, Namrata, Vitti, Robert, Chu, Karen W, Moini, Hadi, Soo, Yuhwen, Cheng, Yenchieh

“…PURPOSE:The effects of repeated intravitreal aflibercept injection (IAI) on the corneal endothelium were studied in patients with unilateral neovascular…”
Get full text

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial by Heier, Jeffrey S., Ho, Allen C., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Brown, David M.

“…Purpose: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular…”
Get full text

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion by Clark, W. Lloyd, MD, Boyer, David S., MD, Heier, Jeffrey S., MD, Brown, David M., MD, Haller, Julia A., MD, Vitti, Robert, MD, Kazmi, Husain, MD, Berliner, Alyson J., MD, PhD, Erickson, Kristine, OD, PhD, Chu, Karen W., MS, Soo, Yuhwen, PhD, Cheng, Yenchieh, PhD, Campochiaro, Peter A., MD

“…Purpose To determine week 52 efficacy and safety outcomes in eyes with macular edema after branch retinal vein occlusion (BRVO) treated with 2 mg intravitreal…”
Get full text

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion by Campochiaro, Peter A., MD, Clark, W. Lloyd, MD, Boyer, David S., MD, Heier, Jeffrey S., MD, Brown, David M., MD, Vitti, Robert, MD, Kazmi, Husain, MD, Berliner, Alyson J., MD, PhD, Erickson, Kristine, PhD, OD, Chu, Karen W., MS, Soo, Yuhwen, PhD, Cheng, Yenchieh, PhD, Haller, Julia A., MD

“…Purpose To compare the efficacy and safety of intravitreal aflibercept injection (IAI) with macular grid laser photocoagulation for the treatment of macular…”
Get full text

Man With Right Flank Pain by Yang, Chih-Hao, Cheng, Chung-Yi, Chu, Karen C.W., Hsu, Chin-Wang, Huang, Wen-Cheng

Get full text

Elderly Male With Fever and Right Flank Pain by Yu, Yi-Chung, Chu, Karen C.W., Hsu, Chin-Wang, Hsu, Yuan-Pin

Get full text

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions by Harvey, Ben-Gary, Maroni, Jaman, O'Donoghue, Kelley A, Chu, Karen W, Muscat, Jolene C, Pippo, Allison L, Wright, Connie E, Hollmann, Charleen, Wisnivesky, Juan P, Kessler, Paul D, Rasmussen, Henrik S, Rosengart, Todd K, Crystal, Ronald G

“…To help define the safety profile of the use of adenovirus (Ad) gene transfer vectors in humans, this report summarizes our experience since April 1993 of the…”
Get more information

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions by Crystal, Ronald G, Harvey, Ben-Gary, Wisnivesky, Juan P, O'Donoghue, Kelley A, Chu, Karen W, Maroni, Jaman, Muscat, Jolene C, Pippo, Allison L, Wright, Connie E, Kaner, Robert J, Leopold, Philip L, Kessler, Paul D, Rasmussen, Henrik S, Rosengart, Todd K, Hollmann, Charleen

“…In this study we analyze the adverse events and abnormal laboratory parameters following local administration of low (<10(9) particle units) and intermediate…”
Get more information

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial by Wykoff, Charles C, Brown, David M, Reed, Kimberly, Berliner, Alyson J, Gerstenblith, Adam T, Breazna, Aurora, Abraham, Prema, Fein, Jordana G, Chu, Karen W, Clark, W Lloyd, Leal, Sergio, Schmelter, Thomas, Hirshberg, Boaz, Yancopoulos, George D, Vitti, Robert

“…Aflibercept, 8 mg, may have greater therapeutic benefits compared with aflibercept, 2 mg, in patients with neovascular age-related macular degeneration (nAMD),…”
Get more information

Intravitreal Nesvacumab (Anti-Angiopoietin 2) Plus Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Randomized Trial by Brown, David M., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Heier, Jeffrey S.

Get full text

Intravitreal Combined Aflibercept + Anti–Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration by Heier, Jeffrey S., Wykoff, Charles C., Waheed, Nadia K., Kitchens, John W., Patel, Sunil S., Vitti, Robert, Perlee, Lorah, Chu, Karen W., Leal, Sergio, Asmus, Friedrich, Son, Vladimir, Schmelter, Thomas, Brown, David M.

“…To compare the efficacy and safety of intravitreal aflibercept + anti–platelet-derived growth factor receptor β (PDGFRβ) combination with intravitreal…”
Get full text

Reply by Clark, W. Lloyd, Boyer, David S., Heier, Jeffrey S., Brown, David M., Haller, Julia A., Vitti, Robert, Kazmi, Husain, Berliner, Alyson J., Erickson, Kristine, Chu, Karen W., Soo, Yuhwen, Cheng, Yenchieh, Campochiaro, Peter A.

Get full text

Reply by Clark, W. Lloyd, MD, Boyer, David S., MD, Heier, Jeffrey S., MD, Brown, David M., MD, Haller, Julia A., MD, Vitti, Robert, MD, Kazmi, Husain, MD, Berliner, Alyson J., MD, PhD, Erickson, Kristine, PhD, OD, Chu, Karen W., MS, Soo, Yuhwen, PhD, Cheng, Yenchieh, PhD, Campochiaro, Peter A., MD

Get full text

Reply by Clark, W Lloyd, Boyer, David S, Heier, Jeffrey S, Brown, David M, Haller, Julia A, Vitti, Robert, Kazmi, Husain, Berliner, Alyson J, Erickson, Kristine, Chu, Karen W, Soo, Yuhwen, Cheng, Yenchieh, Campochiaro, Peter A

Get full text